Literature DB >> 30500891

Limitations of hazard ratios in clinical trials.

Mats J Stensrud1,2, John M Aalen3,4, Odd O Aalen1, Morten Valberg1,5.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 30500891     DOI： 10.1093/eurheartj/ehy770

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  19 in total

1.  Stratified Restricted Mean Survival Time Model for Marginal Causal Effect in Observational Survival Data.

Authors:  Ai Ni; Zihan Lin; Bo Lu
Journal:  Ann Epidemiol       Date:  2021-10-04       Impact factor: 3.797

Review 2.  Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies.

Authors:  Yimei Li; Wei-Ting Hwang; Shannon L Maude; David T Teachey; Noelle V Frey; Regina M Myers; Allison Barz Leahy; Hongyan Liu; David L Porter; Stephan A Grupp; Pamela A Shaw
Journal:  Clin Cancer Res       Date:  2022-09-15       Impact factor: 13.801

3.  Intensive Versus Standard Blood Pressure Lowering and Days Free of Cardiovascular Events and Serious Adverse Events: a Post Hoc Analysis of Systolic Blood Pressure Intervention Trial.

Authors:  Dae Hyun Kim; Curtis Tatsuoka; Zhengyi Chen; Jackson T Wright; Michelle C Odden; Srinivasan Beddhu; Brandon K Bellows; Adam Bress; Thaddeus Carson; William C Cushman; Karen C Johnson; Donald E Morisky; Henry Punzi; Leonardo Tamariz; Song Yang; Lee-Jen Wei
Journal:  J Gen Intern Med       Date:  2022-08-09       Impact factor: 6.473

4.  Focused Information Criterion for Restricted Mean Survival Times: Non-Parametric or Parametric Estimators.

Authors:  Szilárd Nemes; Andreas Gustavsson; Alexandra Jauhiainen
Journal:  Entropy (Basel)       Date:  2022-05-16       Impact factor: 2.738

5.  Assessment of Long-term Benefit of Intensive Blood Pressure Control on Residual Life Span: Secondary Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT).

Authors:  Muthiah Vaduganathan; Brian L Claggett; Stephen P Juraschek; Scott D Solomon
Journal:  JAMA Cardiol       Date:  2020-05-01       Impact factor: 14.676

6.  Counterfactual mediation analysis in the multistate model framework for surrogate and clinical time-to-event outcomes in randomized controlled trials.

Authors:  Isabelle R Weir; Jennifer R Rider; Ludovic Trinquart
Journal:  Pharm Stat       Date:  2021-08-04       Impact factor: 1.894

7.  Intervening on the storage time of RBC units and its effects on adverse recipient outcomes using real-world data.

Authors:  Peter Bruun-Rasmussen; Per Kragh Andersen; Karina Banasik; Søren Brunak; Pär Ingemar Johansson
Journal:  Blood       Date:  2022-06-23       Impact factor: 25.476

Review 8.  Uptake of methodological advances for synthesis of continuous and time-to-event outcomes would maximize use of the evidence base.

Authors:  Suzanne C Freeman; Alex J Sutton; Nicola J Cooper
Journal:  J Clin Epidemiol       Date:  2020-05-12       Impact factor: 6.437

9.  Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial.

Authors:  Kieran F Docherty; Pardeep S Jhund; Brian Claggett; João Pedro Ferreira; Olof Bengtsson; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Anna Maria Langkilde; Felipe A Martinez; Piotr Ponikowski; Marc S Sabatine; Mikaela Sjöstrand; Scott D Solomon; John J V McMurray
Journal:  JAMA Cardiol       Date:  2021-11-01       Impact factor: 30.154

10.  Consequences of Depletion of Susceptibles for Hazard Ratio Estimators Based on Propensity Scores.

Authors:  Bruce Fireman; Susan Gruber; Zilu Zhang; Robert Wellman; Jennifer Clark Nelson; Jessica Franklin; Judith Maro; Catherine Rogers Murray; Sengwee Toh; Joshua Gagne; Sebastian Schneeweiss; Laura Amsden; Richard Wyss
Journal:  Epidemiology       Date:  2020-11       Impact factor: 4.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.